Aeson®
Financiado
The World’s Only Bioprosthetic Auto-regulated Artificial Heart: From Total Artif...
The World’s Only Bioprosthetic Auto-regulated Artificial Heart: From Total Artificial Heart (TAH) to Physiologic Heart Replacement Therapy (PHRT)
At Carmat we have designed and developed Aeson®, the world’s most advanced total artificial heart (TAH), aiming to fulfill an unmet medical need by providing a credible therapeutic alternative to heart transplants for people suffe...
At Carmat we have designed and developed Aeson®, the world’s most advanced total artificial heart (TAH), aiming to fulfill an unmet medical need by providing a credible therapeutic alternative to heart transplants for people suffering from end-stage biventricular heart failure. Aeson® is an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The device is electro-hydraulically driven with a shape close to that of a human heart. Once the Aeson® is powered, it mimics the action of a normal heart, providing mechanical circulatory support and restoring normal blood flow through the body.
Aeson® differs from other existing artificial hearts (or TAH – total artificial hearts) in its unique combination of three features: pulsatility, autoregulation and hemocompatibility. With Aeson®, Carmat is creating a new therapeutic class of physiologic heart replacement therapy (PHRT).
ver más
Duración del proyecto: 17 meses
Fecha Inicio: 2023-04-06
Fecha Fin: 2024-09-30
Fecha Fin: 2024-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-ACCELERATOROPEN-01:
EIC Accelerator Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
12M€
Líder del proyecto
CARMAT
No se ha especificado una descripción o un objeto social para esta compañía.
